Research at the Alzheimer's Disease & Memory Disorders Center

There is currently no cure for Alzheimer's disease and other degenerative memory disorders, but new treatments are available to help alleviate patients' symptoms and slow progression.

Important and innovative research studies are ongoing and continue to shed new light on these illnesses. We now know that the pathologic changes to the brain from Alzheimer’s disease begin many years, probably decades, before symptoms become manifest.

Therefore, current clinical trials are using drugs aimed to slow progression to dementia in the prodromal phase called mild cognitive impairment, and even prevent the disease by treating those at greatest risk before any memory loss has occurred.

To conduct these major trials the Center provides the most up to date facilities to maximize the comfort and experience of the study participants as well as their safety. There are examination rooms, two infusion rooms for administering intravenous antibodies against amyloid, a waiting area, reception area, conference room, television, snacks and coffee. A dedicated computer workstation is used for brain image analysis and driving video research. An on-site laboratory is used to handle research specimens from clinical trials and also houses the Biospecimens Donation Bank containing blood and spinal fluid specimens that are stored and frozen for future research.

Overview

Clinical research is an important part of the work of the Alzheimer's Disease and Memory Disorders Center.

Need More Information About Our Research?

Call 1-844-5-MEMORY (1-844-563-6679).

E-mail memory@lifespan.org

Research areas of interest include:
  • Clinical trials for primary and secondary prevention of Alzheimer’s disease
  • Pharmacoepidemiology in aging and dementia
  • Transcranial magnetic stimulation in frontotemporal dementia and degenerative brain disorders
  • Insulin and “type 3 diabetes” in Alzheimer’s disease
  • Biomarkers and brain imaging studies of preclinical Alzheimer’s and mild cognitive impairment
  • Driving and other behavioral problems in MCI and AD
  • Cognitive screening tests for mild cognitive impairment and normal aging
  • Blood brain barrier in Alzheimer’s and mild cognitive impairment
  • Vascular contributions to development of dementia
  • Quality of life in dementia and caregiver support

Research Leadership at the Center

Brian Ott, MD, is a leader in memory disorder research and he serves as the site’s principal investigator for numerous national clinical trials and studies currently underway at the center. He serves on the steering committees of the Alzheimer's Disease Cooperative Study, a consortium of National Institutes of Health-funded Alzheimer research centers that conducts clinical trials of new therapies for Alzheimer's disease, and the Alzheimer’s Disease Neuroimaging Initiative, a consortium of research centers studying advances in brain imaging techniques and biomarkers to identify the earliest stages of the disease and map its course. He is also a site investigator for the Alzheimer Therapeutic Research Institute, another consortium of academic research centers conducting clinical trials for the prevention and treatment of Alzheimer’s disease, as well as numerous pharmaceutical company-sponsored research studies of new medicines for mild cognitive impairment and Alzheimer's disease.

If you are involved in a research study and have a research appointment:
  • Go to:
    • Ambulatory Patient Center (APC)
      Rhode Island Hospital
      593 Eddy Street
      Providence, RI 02903 
  • Take the elevators to the 7th floor.
  • When you exit the elevators take a left down the first long hallway.
  • Check in at room 712 (half-way down the corridor on the left.)